Regression of atherosclerosis with therapeutic antibodies pipe cleaner or pipe dream?
Ginsburg
Geoffrey S
GS
D000818:Animals; D053299:Apolipoprotein B-100 / Q000276:immunology*; D050197:Atherosclerosis / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage / Q000627:therapeutic use*; D007155:Immunologic Factors / Q000008:administration & dosage / Q000627:therapeutic use*; D051379:Mice; D010446:Peptide Fragments / Q000276:immunology*; D051131:Receptors, Oxidized LDL / Q000502:physiology*; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use
D053299:Apolipoprotein B-100; D007074:Immunoglobulin G; D007155:Immunologic Factors; D010446:Peptide Fragments; D051131:Receptors, Oxidized LDL; D011994:Recombinant Proteins; C524806:apolipoprotein B-100 (661-680), human